MYC targeting by OMO-103 in solid tumors: a phase 1 trial

Topics

MYC oncogene · MYC inhibitor · OMO-103 · miniprotein · Solid tumors · phase 1 clinical trial · dose escalation · 3+3 design · dose-limiting toxicity · pharmacokinetics · recommended phase 2 dose · Infusion reactions · adverse events · stable disease · Response evaluation criteria in solid tumors · Tumor regression · Transcriptomics · target engagement · Tumor biopsy · pharmacodynamic markers · predictive response markers · soluble factors · nonlinear pharmacokinetics · tissue saturation · terminal half-life · intravenous administration · single-agent therapy · advanced solid tumors · oncogene targeting · Undruggable targets · transcriptional programs · Cancer progression · tumor maintenance · antitumor activity · computed tomography · Cancer progression · safety and tolerability